Analyst Price Targets — AORT
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| March 5, 2026 12:57 pm | John McAulay | Stifel Nicolaus | $55.00 | $38.26 | StreetInsider | Artivion (AORT) Reiterated at Buy by Stifel After Physician Conversations |
| December 17, 2025 9:31 am | William Plovanic | Canaccord Genuity | $51.00 | $45.91 | StreetInsider | Canaccord Genuity Reiterates Buy Rating on Artivion Inc. (AORT) |
| November 7, 2025 11:11 am | Suraj Kalia | Oppenheimer | $50.00 | $45.73 | StreetInsider | Artivion Inc. (AORT) PT Raised to $50 at Oppenheimer |
| August 8, 2025 11:09 am | Mike Matson | Needham | $45.00 | $39.27 | StreetInsider | Artivion Inc. (AORT) PT Raised to $45 at Needham |
| October 23, 2024 3:32 am | Daniel Stauder | JMP Securities | $33.00 | $26.53 | StreetInsider | JMP Securities Starts Artivion Inc. (AORT) at Market Outperform |
| August 9, 2024 7:52 am | Suraj Kalia | Oppenheimer | $30.00 | $25.33 | StreetInsider | Artivion Inc. (AORT) PT Raised to $30 at Oppenheimer |
| July 10, 2024 9:08 am | Frank Takkinen | Lake Street | $30.00 | $25.94 | TheFly | Lake Street highlights five 'bargain bin' small cap healthcare ideas for 2H |
| July 2, 2024 8:49 am | Frank Takkinen | Loop Capital Markets | $30.00 | $26.02 | StreetInsider | Artivion Inc. (AORT) PT Raised to $30 at Lake Street Capital Markets |
| May 7, 2024 5:56 am | Mike Matson | Needham | $30.00 | $21.07 | StreetInsider | Artivion Inc. (AORT) PT Raised to $30 at Needham |
Latest News for AORT
Pressure BioSciences (OTCMKTS:PBIO - Get Free Report) and Artivion (NYSE: AORT - Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, institutional ownership, dividends, profitability, analyst recommendations, risk and valuation. Earnings and Valuation This table compares Pressure BioSciences
AORT jumps after FDA approves NEXUS Aortic Arch System, unlocking a potential Endospan acquisition and advancing minimally invasive care for high-risk patients.
Artivion (AORT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Endospan's NEXUS branched endovascular stent graft system shown to effectively treat aortic arch disease, including chronic aortic dissections ATLANTA, April 7, 2026 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that the U.S. Food and Drug Administration (FDA) has approved the premarket approval application (PMA) for the NEXUS®…
SG Americas Securities LLC boosted its position in shares of Artivion, Inc. (NYSE: AORT) by 578.4% in the undefined quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 39,030 shares of the company's stock after acquiring an additional 33,277 shares during the period. SG Americas
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
Senate Trading Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.